Free Republic
Browse · Search
General/Chat
Topics · Post Article

Skip to comments.

New therapy combination yields high remission rates in early-stage Hodgkin lymphoma (97% @ 28 months)
Medical Xpress / University of Texas MD Anderson Cancer Center / Blood Journal ^ | Jan. 25, 2025 | Jade Waddy / Jeremy S. Abramson et al

Posted on 01/25/2026 8:37:07 PM PST by ConservativeMind

Patients with early-stage Hodgkin lymphoma had impressive response rates when treated with a novel combination of therapies—brentuximab vedotin and nivolumab combined with chemotherapy drugs doxorubicin and dacarbazine—according to a study.

"By pairing modern targeted therapies with a shorter course of chemotherapy, we're seeing strong outcomes that improve historical standards and reduce treatment intensity," said senior author Hun Ju Lee, M.D., associate professor of lymphoma.

A total of 154 patients were treated with the novel combination on this trial. Some 96% of patients had some level of response to treatment, and 92% had a complete response with no signs of cancer seen on scans after treatment.

These high response rates were observed in both lower-risk and higher-risk early-stage patients. Among those who achieved a complete response, 96% stayed in complete remission for at least two years. At 28 months of follow-up, 97% of patients were alive without their cancer returning.

Side effects were common for patients but manageable. Of note, no patients experienced febrile neutropenia.

What the results mean for future treatment of these patients Traditionally, patients with early-stage Hodgkin lymphoma are treated with the standard chemotherapy combination, and some also receive radiation. In this study, researchers determined that the new combination may allow patients to receive less chemotherapy.

"This treatment is highly effective and a promising option for people with early-stage, non-bulky Hodgkin lymphoma," Lee said.

(Excerpt) Read more at medicalxpress.com ...


TOPICS: Health/Medicine
KEYWORDS: hodgkinlymphoma; therapy

Click here: to donate by Credit Card

Or here: to donate by PayPal

Or by mail to: Free Republic, LLC - PO Box 9771 - Fresno, CA 93794

Thank you very much and God bless you.

“…brentuximab vedotin and nivolumab combined with chemotherapy drugs doxorubicin and dacarbazine…” It is a short course of chemo.

97% had no cancer at 28 months.

1 posted on 01/25/2026 8:37:07 PM PST by ConservativeMind
[ Post Reply | Private Reply | View Replies]

To: Mazey; ckilmer; goodnesswins; Jane Long; jy8z; ProtectOurFreedom; matthew fuller; telescope115; ...

The “Take Charge Of Your Health” Ping List

This high volume ping list is for health articles and studies which describe something you or your doctor, when informed, may be able to immediately implement for your benefit.

Email me to get on either the “Common/Top Issues” (20 - 25% fewer pings) or “Everything” list.

2 posted on 01/25/2026 8:37:45 PM PST by ConservativeMind (Trump: Befuddling Democrats, Republicans, and the Media for the benefit of the US and all mankind.)
[ Post Reply | Private Reply | To 1 | View Replies]

To: ConservativeMind

I’m guessing they are using AI to figure out these potential combos and then test some of them out.


3 posted on 01/25/2026 8:57:31 PM PST by Secret Agent Man (Gone Galt; not averse to Going Bronson.)
[ Post Reply | Private Reply | To 1 | View Replies]

Disclaimer: Opinions posted on Free Republic are those of the individual posters and do not necessarily represent the opinion of Free Republic or its management. All materials posted herein are protected by copyright law and the exemption for fair use of copyrighted works.

Free Republic
Browse · Search
General/Chat
Topics · Post Article

FreeRepublic, LLC, PO BOX 9771, FRESNO, CA 93794
FreeRepublic.com is powered by software copyright 2000-2008 John Robinson